Zhejiang Orient Gene Biotech Co Ltd (688298) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has a cash flow conversion efficiency ratio of -0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-30.52 Million ≈ $-4.47 Million USD) by net assets (CN¥6.49 Billion ≈ $950.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zhejiang Orient Gene Biotech Co Ltd (688298) balance sheet quality index to measure how much of total assets are equity-financed.
Zhejiang Orient Gene Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Zhejiang Orient Gene Biotech Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Zhejiang Orient Gene Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mühlbauer Holding AG
XETRA:MUB
|
0.114x |
|
Guangdong Piano Customized Furniture Co Ltd
SHE:002853
|
0.016x |
|
LX Semicon Co. Ltd
KQ:108320
|
0.018x |
|
CARE Ratings Limited
NSE:CARERATING
|
0.029x |
|
Guangzhou Pearl River Industrial Development Co Ltd
SHG:600684
|
-0.001x |
|
First Sensor AG
F:SIS
|
0.047x |
|
Universal Health Realty Income Trust
NYSE:UHT
|
0.081x |
|
Grupa Azoty S.A.
WAR:ATT
|
0.476x |
Annual Cash Flow Conversion Efficiency for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Zhejiang Orient Gene Biotech Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥6.79 Billion ≈ $993.80 Million |
CN¥-348.33 Million ≈ $-50.97 Million |
-0.051x | +75.83% |
| 2023-12-31 | CN¥7.55 Billion ≈ $1.10 Billion |
CN¥-1.60 Billion ≈ $-234.43 Million |
-0.212x | -158.95% |
| 2022-12-31 | CN¥8.32 Billion ≈ $1.22 Billion |
CN¥3.00 Billion ≈ $438.40 Million |
0.360x | -52.35% |
| 2021-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
CN¥5.20 Billion ≈ $761.49 Million |
0.755x | +3.44% |
| 2020-12-31 | CN¥2.45 Billion ≈ $358.72 Million |
CN¥1.79 Billion ≈ $261.98 Million |
0.730x | +242.35% |
| 2019-12-31 | CN¥254.13 Million ≈ $37.19 Million |
CN¥54.21 Million ≈ $7.93 Million |
0.213x | +0.12% |
| 2018-12-31 | CN¥208.03 Million ≈ $30.44 Million |
CN¥44.33 Million ≈ $6.49 Million |
0.213x | -12.27% |
| 2017-12-31 | CN¥138.12 Million ≈ $20.21 Million |
CN¥33.54 Million ≈ $4.91 Million |
0.243x | +103.04% |
| 2016-12-31 | CN¥98.72 Million ≈ $14.45 Million |
CN¥11.81 Million ≈ $1.73 Million |
0.120x | -- |
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more